Anzeige
Mehr »
Sonntag, 28.09.2025 - Börsentäglich über 12.000 News
Das Paradox-Becken hat sich bewiesen - und American Critical sitzt direkt auf dem nächsten Milliardenfund
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CPAM | ISIN: US7867001049 | Ticker-Symbol: 0O2
Tradegate
25.09.25 | 17:18
6,200 Euro
-0,80 % -0,050
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
SAGIMET BIOSCIENCES INC Chart 1 Jahr
5-Tage-Chart
SAGIMET BIOSCIENCES INC 5-Tage-Chart
RealtimeGeldBriefZeit
6,2006,35016:46
6,1506,40026.09.

Aktuelle News zur SAGIMET BIOSCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
SAGIMET BIOSCIENCES Aktie jetzt für 0€ handeln
MiSagimet Biosciences Inc.: Sagimet Biosciences Announces Upcoming Panel Participation at Fierce Biotech Week4
17.09.Sagimet Biosciences Inc.: Positive Phase 3 Results for Denifanstat for the Treatment of Moderate to Severe Acne to be Presented at the EADV Congress 2025 by Partner Ascletis173Denifanstat met all primary and secondary endpoints versus placebo Denifanstat was generally well tolerated Sagimet initiated first-in-human Phase 1 clinical trial of a second FASN inhibitor, TVB-3567...
► Artikel lesen
10.09.Sagimet Biosciences Inc.: Sagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development Summit3
22.08.Sagimet Biosciences Inc. - 8-K, Current Report2
13.08.Sagimet Biosciences Inc Q2 Loss Increases, But Beats Estimates3
13.08.Sagimet Biosciences GAAP EPS of -$0.32 beats by $0.214
13.08.Sagimet Biosciences Inc.: Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates426Denifanstat met all primary and secondary endpoints in Phase 3 clinical trial in moderate to severe acne conducted by license partner Ascletis in China Initiated first-in-human Phase 1 clinical trial...
► Artikel lesen
13.08.Sagimet Biosciences Inc. - 8-K, Current Report4
13.08.Sagimet Biosciences Inc. - 10-Q, Quarterly Report2
11.08.Wedbush initiates coverage on Sagimet Biosciences stock with Outperform rating4
24.07.Sagimet gains as Canaccord Genuity starts with Buy on potential against MASH12
17.06.Sagimet stock holds steady as JMP reiterates $31 price target20
09.06.Sagimet Biosciences Inc.: Sagimet Biosciences to Host Virtual KOL Event, "A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne" on June 16, 202512
04.06.Sagimet Biosciences Stock Gains 14% After Positive Phase 3 Acne Trial Results10
04.06.Sagimet's Partner Achieves Positive Results With Oral Acne Drug In Phase 3 Acne Trial In China, Stock Jumps6
04.06.Sagimet Biosciences shares soar on positive acne treatment trial results6
04.06.Sagimet climbs as acne therapy hits main goals in late-stage trial in China2
04.06.Why Sagimet Biosciences Is Rising In Pre-market?3
04.06.Sagimet Biosciences Inc. - 8-K, Current Report2
04.06.Sagimet Biosciences Inc.: Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis203Denifanstat met all primary and secondary endpoints versus placebo Denifanstat was well tolerated Oral FASN inhibitors offer a novel mechanism of action for the potential treatment of moderate to...
► Artikel lesen
Weiter >>
30 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2